.png)
.png)
PBS Changes from 1 July2025
- Anja Locke
- Jul 1
- 4 min read
Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1st July 2025.
This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit pbs.gov.au. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.
Cystic fibrosis
Elexacaftor + tezacaftor + ivacaftor (&) ivacaftor (elexacaftor 100 mg+ tezacaftor 50 mg+ ivacaftor 75 mg granules [28] (&) ivacaftor 75 mg granules [28], 56 sachets; elexacaftor 80 mg + tezacaftor 40 mg + ivacaftor 60 mg granules [28] (&) ivacaftor 59.5 mg granules [28], 56 sachets; elexacaftor 50 mg+ tezacaftor 25 mg+ ivacaftor 37.5 mg tablet [56] (&) ivacaftor 75 mg tablet [28], 84; elexacaftor 100 mg + tezacaftor 50 mg + ivacaftor 75 mg tablet [56] (&) ivacaftor 150 mg tablet [28], 84) (Trikafta®) for the treatment of cystic fibrosis has had an update to restrictions. Authority applications for initial and continuing treatments can be made either in real-time using the Online PBS Authorities system or in writing.
Severe active rheumatoid arthritis; severe active juvenile idiopathic arthritis; severe psoriatic arthritis; severe chronic plaque psoriasis; ankylosing spondylitis
Etanercept (50 mg/ml injection, 4 x 1 ml pen devices) (Nepexto®) is a biosimilar now listed on the PBS for the treatment of severe active rheumatoid arthritis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, severe chronic plaque psoriasis and ankylosing spondylitis.
Branch retinal vein occlusion with macular oedema; central retinal vein occlusion with macular oedema
Faricimab (6 mg/0.05 ml intraocular injection, 0.05 ml syringe) (Vabysmo®) is now listed on the PBS for the treatment of branch retinal vein occlusion with macular oedema and central retinal vein occlusion with macular oedema. Authority applications for initial treatment can be made either in real-time using the Online PBS Authorities system or in writing. Prescriptions for continuing treatment are Authority required (STREAMLINED).
Early breast cancer
Ribociclib (200 mg tablet) (Kisqali®) is now listed on the PBS for the treatment of early breast cancer. Authority applications for initial and continuing treatments can be made either in realtime using the Online PBS Authorities system or by telephone.
Locally advanced or metastatic cholangiocarcinoma
lvosidenib (250 mg tablet) (Tibsovo®) is now listed on the PBS for the treatment of locally advanced or metastatic cholangiocarcinoma. Prescriptions for treatment are Authority required (STREAMLINED).
Cytomegalovirus infection and disease
Maribavir (200 mg tablet) (Livtencity®) is now listed on the PBS for the treatment of cytomegalovirus infection and disease. Prescriptions for treatment are Authority required (STREAMLINED).
Unresectable or metastatic urothelial carcinoma
Nivolumab (40 mg/4 ml injection, 4 ml vial; 100 mg/10 ml injection, 10 ml vial) (Opdivo®) is now listed on the PBS for the treatment of unresectable or metastatic urothelial carcinoma.
Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).
Trachoma; urethritis; cervicitis
Azithromycin (500 mg tablet) (Azithromycin Tablets, USP 500 mg (Precision Dose, USA)®) for the treatment of trachoma; urethritis and cervicitis is now listed on the PBS for the current supply shortage under Section 19A. Azithromycin is listed as a restricted benefit.
Attention deficit hyperactivity disorder
Methylphenidate (18 mg; 27 mg; 36 mg; 54 mg modified release tablet) (Concerta (Switzerland)
®) for the treatment of attention deficit hyperactivity disorder is now listed on the PBS for the current supply shortage under Section 19A. Authority applications can be made either in real time using the Online PBS Authorities system or by telephone.
Bone pain; chronic arthropathies; severe pain
Naproxen (125 mg/5 ml oral liquid, 474 ml) (Pediapharm Naproxen Suspension 25 mg/ml (Medexus Pharma, Canada)®) for the treatment of bone pain; chronic arthropathies (including osteoarthritis) and severe pain is now listed on the PBS for the current supply shortage under Section 19A. Prescriptions for the treatment of bone pain and chronic arthropathies (including osteoarthritis) are Authority required (STREAMLINED). Naproxen for the treatment of severe pain in palliative care is listed as a restricted benefit
1 July 2025 delisted PBS listings
Inflammation of the eye
Dexamethasone (0.1% eye drops, 5 ml) (Maxidex®) has been delisted.
Prevention of chronic, stable angina pectoris due to coronary artery disease
Glyceryl trinitrate (15 mg/24 hours patch) (Minitran 15®) has been delisted.
Systemic lupus erythematosus
Anifrolumab (300 mg/2 ml injection, 2 ml vial) (Saphnelo®) no longer has a listing for Grandfather arrangements.
For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities.
Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html.
Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.
For more information go to servicesaustralia.gov.au/hpos. To learn more about these updates, please contact Services Australia directly.
At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention, and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.
Comments